儿童、青少年及青年非霍奇金淋巴瘤的新型靶向治疗药物
儿童、青少年及青年非霍奇金淋巴瘤多为侵袭性淋巴瘤,采用多药化疗或免疫化疗方案总体生存率高但急性和长期毒性发生率高,复发或难治性患者结局不佳。本综述聚焦儿童、青少年及青年非霍奇金淋巴瘤相关药物,汇总了体液免疫和细胞免疫治疗、相关信号通路小分子抑制剂及表观遗传修饰剂等新型治疗方法的开发现状。
要点
- 儿童、青少年及青年非霍奇金淋巴瘤多为侵袭性淋巴瘤,总体生存率高但治疗急性和长期毒性发生率高。
- 复发或难治性非霍奇金淋巴瘤患者结局不佳,亟需改善结局并降低毒性的新型治疗方法。
- 在研方法包括体液免疫和细胞免疫治疗、信号通路小分子抑制剂及表观遗传修饰剂。
核心结论
- 儿童、青少年及青年非霍奇金淋巴瘤总体生存率高,但当前治疗急性和长期毒性发生率高,复发或难治性患者结局不佳。
- 改善结局并降低当前方案相关毒性的新型治疗方法对T细胞和B细胞非霍奇金淋巴瘤均至关重要。
研究设计与样本
- 综述,汇总儿童、青少年及青年非霍奇金淋巴瘤相关新型治疗药物的开发现状。
主要发现
- 在研的潜在治疗方法包括体液免疫和细胞免疫治疗、相关信号通路小分子抑制剂及表观遗传修饰剂。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of malignancies. Most NHLs in children, adolescent and young adult patients are aggressive lymphomas that are generally treated with multi-agent chemotherapy or immunochemotherapy regimens. While overall survival is high, the treatment can lead to a high rate of acute and long-term toxicity. However, in the rarer instance of relapsed or refractory disease, outcomes are dismal. Novel therapeutic approaches to the treatment of both T-cell and B-cell NHLs are critical to improve outcomes while also minimising the associated toxicity of current treatment regimes. Potential therapeutic approaches in development include humoral and cellular immunotherapies, small molecule inhibitors of relevant signalling pathways and epigenetic modifying agents. In this review, we will highlight the current state of development of agents of interest with a focus on agents relevant to childhood, adolescent and young adult NHL.
引用
- Barth MJ, Minard-Colin V. Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. Br J Haematol. 2019. PMID: 30701541. doi:10.1111/bjh.15783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。